Recombinant Human Hyaluronidase
Nodular Lymphocyte Predominant Hodgkin Lymphoma
National Cancer Institute (NCI)UNKNOWNPhase 2/3Active
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 89/ 100
Competitive context
8 Active assets in the Nodular Lymphocyte Predominant Hodgkin Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Adriamycin National Cancer Institute (NCI) | Phase 3 | BBB |
Prednisone National Cancer Institute (NCI) | Phase 3 | BBB |
Cyclophosphamide National Cancer Institute (NCI) | Phase 3 | BB |
(+)-Vincristine Children's Oncology Group | Phase 3 | BB |
Nivestim Children's Oncology Group | Phase 3 | BB |
View all 30 →
Same molecule, other indications
Recombinant Human Hyaluronidase is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →